Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1062-1068

  Fukuda, Toshio ^a   Tsuji, Naoki ^a   Honda, Yuko ^a   Kamisato, Chikako ^a   Morishima, Yoshiyuki ^a   Shibano, Toshiro ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Edoxaban; Factor Xa inhibitor; Fondaparinux; Shear rate; Thrombosis

Indexed keywords

EDOXABAN; FONDAPARINUX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITHROMBOTIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BLOOD VISCOSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FIBRIN DEPOSITION; FIBRIN FORMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; SHEAR RATE; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD FLOW VELOCITY; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; FACTOR XA; HUMANS; MALE; POLYSACCHARIDES; PYRIDINES; RATS; RATS, WISTAR; THIAZOLES; THROMBOSIS; VENA CAVA, INFERIOR;

EID: 82555191255     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-07-0451     Document Type: Article

References (28)

1. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-1106.
2. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119: 22S-38S.
3. Morris TA, Castrejon S, Devendra G, et al. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest 2007; 132: 1131-1139.
4. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27: 1238-1247.
5. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542-1549.
6. Fuji T, Fujita S, Tachibana S, et al. Efficacy and Safety of Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Arthroplasty: STARS J-V trial. Blood 2010; 116: Abstract 3320.
7. Fujita S, Fuji T, Tachibana S, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Pathophysiol Haemost Thromb 2010; 37: A95 (Abstract P366).
8. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-641.
9. Nadar SK, Goyal D, Shantsila E, et al. Fondaparinux: an overview. Expert Rev Cardiovasc Ther 2009; 7: 577-585.
10. Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003; 89: 112-121.
11. Hobbelen PM, van Dinther TG, Vogel GM, et al. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 265-270.
12. Bal dit Sollier C, Kang C, Berge N, et al. Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis. J Thromb Haemost 2004; 2: 925-930.
13. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6: 820-829.
14. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939- an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
15. Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 2009; 7: 1313-1320.
16. Morishima Y, Tanabe K, Terada Y, et al. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997; 78: 1366-1371.
17. Abboud MA, Needle SJ, Burns-Kurtis CL, et al. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor. J Cardiovasc Pharmacol 2008; 52: 66-71.
18. Orvim U, Barstad RM, Vlasuk GP, et al. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 2188-2194.
19. Lavelle SM, Iomhair MM. The reliability of thrombotic tendency measured by intravascular wires in the rat. Thromb Res 1997; 87: 353-357.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
21. André P, Arbeille B, Drouet V, et al. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. Arterioscler Thromb Vasc Biol 1996; 16: 56-63.
22. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-280.
23. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, et al. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006; 7: 3902-3906.
24. van der Meijden PE, Munnix IC, Auger JM, et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 114: 881-890.
25. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98: 883-888.
26. Schoen P, Lindhout T. Flow and the inhibition of prothrombinase by antithrombin III and heparin. Blood 1991; 78: 118-124.
27. Olson ST, Björk I, Sheffer R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-12538.
28. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50: 1742-1751.